Sugi Predict

Sugi Predict / Compounds / SCHEMBL19205451

SCHEMBL19205451

SCHEMBL19205451

Oc1ccccc1C1(O)CCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.43
▸ MAPT P10636 3/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ ALOX15 P16050 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ CA12 O43570 1/20 0.43
▸ GMNN O75496 1/20 0.43
▸ EGFR P00533 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ FYN P06241 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ CA3 P07451 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ MMP9 P14780 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ CA4 P22748 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6058582 0.93 MEN1 (0.41) ALDH1A1MAPTTDP1SMN1; SMN2ALOX15
SCHEMBL17733195 0.93 MEN1 (0.41) ALDH1A1MAPTTDP1SMN1; SMN2ALOX15
SCHEMBL29484741 0.93 MEN1 (0.41) ALDH1A1MAPTTDP1SMN1; SMN2ALOX15
SCHEMBL15352660 0.81 ALDH1A1 (0.42) ALDH1A1MAPTTDP1SMN1; SMN2ALOX15
SCHEMBL10513090 0.80 ALDH1A1 (0.43) ALDH1A1MAPTTDP1SMN1; SMN2ALOX15
SCHEMBL4069650 0.79 OPRL1 (0.40) TDP1SIGMAR1PDK2THRBADORA3
SCHEMBL17982827 0.79 OPRM1 (0.56) ALDH1A1HPGDL3MBTL1MEN1KMT2A
SCHEMBL30678365 0.79 OPRM1 (0.56) ALDH1A1HPGDL3MBTL1MEN1KMT2A
SCHEMBL29710660 0.79 ALOX15 (0.38) ALDH1A1MAPTTDP1SMN1; SMN2ALOX15
SCHEMBL28994161 0.79 OPRM1 (0.56) ALDH1A1MAPTSMN1; SMN2SIGMAR1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12168643-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2024-12-17 — — US disclosed
CN-111491628-B Phenoxy acids for the treatment of neuromuscular disorders NMD制药股份公司 2023-10-13 — — CN disclosed
US-11591284-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2023-02-28 — — US disclosed
US-20220306564-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2022-09-29 — — US disclosed
EP-3986853-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2022-04-27 — — EP disclosed
EP-3723746-B1 PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA AS (DK) 2022-02-23 — — EP disclosed
WO-2020254553-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2020-12-24 — — WO disclosed
WO-2020254553-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2020-12-24 — — WO disclosed
EP-3723746-A1 PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2020-10-21 — — EP disclosed
CN-111491628-A Phenoxy acids for the treatment of neuromuscular disorders NMD制药股份公司 2020-08-04 — — CN disclosed
WO-2019115780-A1 PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2019-06-20 — — WO disclosed
WO-2019115780-A1 PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2019-06-20 — — WO disclosed
US-20190183812-A1 Compounds For The Treatment Of Neuromuscular Disorders NMD PHARMA A/S (DK) 2019-06-20 — — US disclosed
US-9944596-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-04-17 — — US disclosed
US-9944596-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-04-17 — — US disclosed
US-9944596-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-04-17 — — US disclosed
EP-3210971-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-08-30 — — EP disclosed
US-20170233339-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-08-17 — — US disclosed
US-20170233339-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-08-17 — — US disclosed
US-20170233339-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306564-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS RYR1, SMN1; SMN2, CACNB1 ALDH1A1 818/4885MAPT 3596/4885TDP1 218/4885
US-20170233339-A1 HETEROCYCLIC COMPOUND RBP4, RBP1, RARA ALDH1A1 485/4885MAPT 2734/4885TDP1 3869/4885
US-20190183812-A1 Compounds For The Treatment Of Neuromuscular Disorders RYR1, CACNB1, RYR2 ALDH1A1 1343/4885MAPT 3698/4885TDP1 277/4885
US-12168643-B2 Compounds for the treatment of neuromuscular disorders RYR1, SMN1; SMN2, CACNB1 ALDH1A1 818/4885MAPT 3596/4885TDP1 218/4885
US-11591284-B2 Compounds for the treatment of neuromuscular disorders RYR1, CACNB1, CACNA1S ALDH1A1 522/4885MAPT 2803/4885TDP1 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.